Since the passage of the 21st Century Cures Act in 2016, Food and Drug Administration (FDA) approvals for new medical products have relied on fewer studies, according to a study published Aug. 26, 2026, in the PLOS ONE by researchers from the Stanford University School of Medicine Clinical Excellence Research Center, Oregon State University and UCLA, U.S.
FDA Approvals Post-21st Century Cures Act: Fewer Studies Required
Since the 21st Century Cures Act was enacted in 2016, FDA approvals for new medical products have increasingly depended on fewer studies, as highlighted by a recent study from U.S. researchers. This trend raises concerns about the rigor of medical product evaluations. For Iran, this could impact the availability and safety of medical products in the market.
👥 Key Players
📰 What Happened
A recent study indicates that since the 21st Century Cures Act was enacted in 2016, the FDA has been approving new medical products with fewer studies required for evaluation. This trend raises concerns about the thoroughness of product assessments.
- The FDA's approval process has become less rigorous since 2016.
- Concerns have been raised regarding the safety and efficacy of medical products as a result.
💡 Why It Matters
📚 Background
The 21st Century Cures Act was designed to expedite the development of new medical treatments, but its implementation has led to debates about the balance between speed and safety in medical product approvals.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%